Real world study of the continuation of bevacizumab beyond disease progression after first‐line treatment containing bevacizumab in Chinese patients with advanced non‐small cell lung cancer

BACKGROUND: Bevacizumab (Bev) plus platinum‐based chemotherapy is a standard first‐line treatment option for advanced non‐squamous non‐small cell lung cancer (NS‐NSCLC). We evaluated the efficacy and safety of continuing Bev in Chinese patients with advanced NS‐NSCLC progression after first‐line tre...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Thorac Cancer
Hlavní autoři: Xing, Puyuan, Mu, Yuxin, Wang, Yan, Hao, Xuezhi, Zhu, Yixiang, Hu, Xingsheng, Wang, Hongyu, Liu, Peng, Lin, Lin, Wang, Zhijie, Li, Junling
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons Australia, Ltd 2018
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6275823/
https://ncbi.nlm.nih.gov/pubmed/30324773
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12886
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky